<DOC>
	<DOCNO>NCT02633527</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multicenter , 5-arm , parallel-group , fix dose study assess efficacy safety SPN-812 ER treatment child age 6-12 year ADHD . The primary objective ass effect SPN-812 ER reduce ADHD symptom . This measure use ADHD-RS-IV rating scale .</brief_summary>
	<brief_title>Efficacy Safety SPN-812 ER Children With ADHD</brief_title>
	<detailed_description />
	<criteria>1 . Healthy male female subject , 612 year age , inclusive , diagnosis ADHD accord Diagnostic Statistical Manual Mental DisordersIV ( DSM IV ) , confirm Mini International Neuropsychiatric Interview Children Adolescents ( MINIKID ) . 2 . ADHDRSIVParent Version : Investigator Administered Scored score least 26 . 3 . CGIS score least 4 4 . Weight least 20 kg . 5 . Free medication treatment ADHD psychosis least one week prior enrollment . 1 . Current lifetime diagnosis major depressive disorder , bipolar disorder , personality disorder , Tourette 's disorder , psychosis otherwise specify . 2 . Currently meet DSMIV criterion pervasive developmental disorder , obsessive compulsive disorder , posttraumatic stress disorder , anxiety disorder primary diagnosis . 3 . Significant systemic disease . 4 . Evidence suicidality within six month Screening Screening . 5 . BMI great 95th percentile appropriate age gender . 6 . Pregnancy refusal practice abstinence study female subject childbearing potential ( FOCP ) . 7 . Substance alcohol use last three month . 8 . Positive urine screen cotinine , alcohol , drug abuse Screening .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>